Delving into the Latest Updates on Alinastine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Lamiakast

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesEye DiseasesRespiratory Diseases+ [1]

Active Indication-

Inactive Indication

AsthmaConjunctivitis, AllergicSkin Diseases

Originator Organization

Faes Farma SA

Active Organization-

Inactive Organization

Faes Farma SA

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC28H39N3O

InChIKeyNPWTVYBPSXCRPM-UHFFFAOYSA-N

CAS Registry154541-72-7

A solid-phase extraction (SPE) method for sample clean-up followed by a reversed-phase HPLC procedure for the assay of alinastina (pINN) in biological fluids is reported. The effects of the sample pH, composition of the washing and elution solvents and the nature of the SPE cartridge on recovery were evaluated. The selectivity of SPE was examined using spiked rat urine and plasma samples and the CH and PH cartridges gave rise to the cleanest extracts. The recoveries obtained in spiked rat urine and plasma samples were 91.2+/-2.7 and 99.9+/-2.8%, respectively. The proposed SPE method coupled off-line with a reserved-phase HPLC system with fluorimetric detection was applied to the quantitation of alinastine in real rat urine samples. The analytical method was also applied and validated for the determination of alinastine in dog plasma. The recovery from spiked dog plasma samples using the PH cartridge was around 65%. The within-day and between-day precisions were 7 and 12%, respectively. The detection and quantitation limits in dog plasma were 0.024 and 0.078 microg/ml, respectively.

100 Deals associated with Alinastine

Login to view more data